Novel agonists and antogonists of chemokine receptors

Information

  • Research Project
  • 6584391
  • ApplicationId
    6584391
  • Core Project Number
    R44AI051136
  • Full Project Number
    2R44AI051136-02
  • Serial Number
    51136
  • FOA Number
  • Sub Project Id
  • Project Start Date
    1/1/2003 - 21 years ago
  • Project End Date
    12/31/2004 - 19 years ago
  • Program Officer Name
    SOMERS, SCOTT D.
  • Budget Start Date
    1/1/2003 - 21 years ago
  • Budget End Date
    12/31/2003 - 20 years ago
  • Fiscal Year
    2003
  • Support Year
    2
  • Suffix
  • Award Notice Date
    -
Organizations

Novel agonists and antogonists of chemokine receptors

[unreadable] DESCRIPTION (provided by the applicant): A key event in the initiation and maintenance of an inflammatory response is the recruitment of immune effector cells to the site of a local immune response. This recruitment and retention is mediated by chemoattractant compounds, of which chemokines are an essential component. The chemokine family consists of ~50 small proteins, which mediate effects through G-protein coupled chemokine receptors expressed on target cells.The long term objective of this study is to isolate and characterize effectors which regulate the chemokine / chemokine receptor interaction. To achieve this our phase I objective was to develop a Xenopus oocyte assay to identify and isolate novel peptidyl agonists / antagonists of the chemokine receptors. In phase I feasibility studies we developed an assay using the CCR3 receptor, and the chemokine eotaxin as a positive control. We also developed a peptide expression system, and initiated library screening.In phase II studies we propose to extend our assay development to all known chemokine receptors, and to characterize the agonist and antagonist effectors isolated in our assay. The results of these studies will be used in the next phase of research, the development of lead compounds

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R44
  • Administering IC
    AI
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    489461
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:489461\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ICOGENEX CORPORATION
  • Organization Department
  • Organization DUNS
    836856351
  • Organization City
    SEATTLE
  • Organization State
    WA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    98103
  • Organization District
    UNITED STATES